Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence SALEEYTKKLNTQ
Primary information
sequence IDSeq_6852
Peptide sequenceSALEEYTKKLNTQ
CancerPDF_ID CancerPDF_ID74, CancerPDF_ID1578, CancerPDF_ID9547,
PMID16896061,21136997,21533267
Protein NameApolipoprotein A-I,Apolipoprotein A-I,Apolipoprotein A-I
UniprotKB Entry NameAPOA1_HUMAN,APOA1_HUMAN,APOA1_HUMAN
FluidSerum,Serum,Serum
M/Z762.85,1523.78314,508.93
Charge1,1,3
Mass (in Da)1524.78,NA,NA
fdrNA,NA,NA
Profiling TechniqueMALDI-TOF,LC-MS,LC-MS
Peptide Identification techniqueQ/TOF MS/MS,LC-MS-MS/MS,LC/MS/MS
Quantification TechniqueNA,LC-ESI-MS,Multiple Reaction Monitoring
Labelled/Label FreeLabel Free,Label Free,Label Free
FDRNA,NA,1.49
CancerPDF_ID CancerPDF_ID74, CancerPDF_ID1578, CancerPDF_ID9547,
p-Value1.00E-05,NA,NA
SoftwareMASCOT,MASCOT(v. 2.2.01),MASCOT
Length13,13,13
Cancer TypeMetastatic thyroid carcinomas,Colorectal cancer,Lung adenocarcinoma
DatabaseNCBI refseq Protein Database,SwissProt Database,Swissprot Database (57.4)
ModificationNA,NA,NA
Number of Patients40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,30 patients and 30 healthy controls,62 lung adenocarcinoma and 30 healthy control
RegulationNA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal"
ValidationIndependent validation,Leave One out Cross validation,MRM-based validation of 19 candidates
Sensitivity95% on independent dataset,NA,NA
Specificity95% on independent dataset,NA,NA
AccuracyNA,NA,NA
Peptide AtlasNA
IEDB120086